H.C. Wainwright analyst Andrew Fein assumed coverage of Akero Therapeutics (AKRO) with a Buy rating and $72 price target Th firm says efruxifermin’s cirrhosis reversal and Phase 3 readouts support a bullish share view.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Akero Therapeutics’ Efruxifermin Study: A Potential Game-Changer for NASH Treatment
- Akero Therapeutics’ Phase 3 NASH Study: A Potential Game-Changer?
- Akero Therapeutics’ efruxifermin shows efficacy in Phase 2b MASH, fibrosis trial
- Strong Financial Position and Promising Clinical Developments Support Buy Rating for Akero Therapeutics
- Akero Therapeutics Advances in MASH Treatment Development